Project Grant R34HL177448
- The federal Project Grant award in the amount of $503,870.00 was provided by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) to Drexel University. The award is focused on developing a mechanistic understanding of how fetal hemoglobin (HbF) modulates the polymerization of sickle cell hemoglobin (HbS), which is the root cause of sickle cell disease. The research aims to address critical knowledge gaps that limit the rational optimization of...
- The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. government, awarded a $683,048 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The purpose of this 5-year project grant, with a start date of May 1, 2025 and a completion date of March 31, 2030, is to investigate the cellular and molecular mechanisms by which the zinc ion importer ZIP8 impacts the formation of the...
- This federal Project Grant award for $111,626.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage populations and their role in pulmonary hypertension associated with sickle cell disease. The 2-year research project aims to determine if targeting iron release can modify CD169+ macrophages and adaptive immune cells, and if ablation of CD169+ macrophages can inhibit the progression of...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides funding of $2,968,063.02 to the Children's Research Institute to conduct a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous citrulline for treating vaso-occlusive crisis in sickle cell disease. The study aims to determine if the administration of citrulline, which plays a role in nitric oxide production, can lead to...
- This federal Project Grant award of $225,101 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancies in sickle cell disease patients. The key objectives of this 2-year project are to: 1) Perform experiments to understand how increased oxidative stress and DNA damage in hematopoietic stem and progenitor cells lead to the development of clonal...
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
- This Project Grant award of $154,796.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center aims to use non-invasive neuroimaging techniques to investigate cerebral oxygen utilization in patients with sickle cell disease. The goal is to develop biomarkers that can be used to assess ischemic risk and evaluate the impact of emerging treatments on brain health. The project will explore how abnormal...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $536,468 to the University of California, San Diego (UC San Diego) to conduct research on protein aggregation in hematopoietic stem cells (HSCs). The project aims to investigate how HSCs, which regenerate blood and immune cells, preferentially traffic misfolded proteins to aggresomes to maintain fitness and self-renewal, and how this process is impacted by...
- This $755,853.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to target the pathophysiology of sickle cell-related kidney disease using SGLT2 inhibitors. The key products and services to be delivered through this funding include: Evaluating whether the SGLT2 inhibitor empagliflozin improves biomarkers of kidney function and injury, as well as measures of kidney perfusion, oxygenation, and fibrosis using functional...
This federal Project Grant award of $449,538 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research initiative titled "ZINC SUPPLEMENTATION IN SCD: A PRECURSOR TO THE THINK ZINC FOR BONES TRIAL". The grant aims to investigate the potential of zinc supplementation to improve bone health outcomes for individuals with sickle cell disease (SCD), a hemoglobin disorder that often results in early onset bone morbidity. The 2-year project, running from Aug 2025 to Jul 2027, will be conducted by researchers at the University of California, San Francisco (UCSF). The overarching goal is to generate evidence on whether zinc supplementation can help mitigate the deterioration of bone mass and structure experienced by many SCD patients, an area that has received limited research attention despite the significant clinical need.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $449.5k | 7/31/25 |